GLENMARK - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | GLENMARK | Market Cap | 62,133 Cr. | Current Price | 2,202 ₹ | High / Low | 2,474 ₹ |
| Stock P/E | 38.8 | Book Value | 856 ₹ | Dividend Yield | 0.11 % | ROCE | 6.51 % |
| ROE | 6.58 % | Face Value | 1.00 ₹ | DMA 50 | 2,224 ₹ | DMA 200 | 2,067 ₹ |
| Chg in FII Hold | 1.15 % | Chg in DII Hold | -0.81 % | PAT Qtr | 295 Cr. | PAT Prev Qtr | 426 Cr. |
| RSI | 49.4 | MACD | -34.4 | Volume | 9,88,095 | Avg Vol 1Wk | 5,46,499 |
| Low price | 1,612 ₹ | High price | 2,474 ₹ | PEG Ratio | 84.4 | Debt to equity | 0.00 |
| 52w Index | 68.4 % | Qtr Profit Var | 9.79 % | EPS | -7.12 ₹ | Industry PE | 32.5 |
📊 Glenmark shows weak efficiency with low [ROCE](ca://s?q=Explain_ROCE) (6.51%) and [ROE](ca://s?q=Explain_ROE) (6.58%), which are significantly below industry standards. Despite being debt-free, the company’s [PEG ratio](ca://s?q=Explain_PEG_ratio) of 84.4 highlights severe overvaluation relative to growth. The [P/E valuation](ca://s?q=Explain_P/E_ratio) of 38.8 is also higher than the industry average (32.5). Dividend yield (0.11%) is negligible, offering little income support. EPS is negative (-7.12 ₹), raising concerns about profitability sustainability.
💡 The ideal entry price zone would be near 1,600–1,750 ₹, close to the 52-week low (1,612 ₹) and below DMA levels (2,067–2,224 ₹), providing a margin of safety. RSI (49.4) indicates neutral momentum, while MACD (-34.4) suggests bearish sentiment, making caution essential before accumulation.
📈 For existing holders, the exit strategy should be short-to-medium term rather than long-term, given weak efficiency metrics and overvaluation. Consider reducing exposure if the stock revisits 2,350–2,450 ₹ (recent highs). Long-term holding is risky unless profitability improves significantly.
✅ Positive
- 📌 Debt-free balance sheet ensures financial stability.
- 📌 Institutional interest rising from FIIs (+1.15%).
- 📌 Quarterly PAT of 295 Cr, though lower than previous quarter.
⚠️ Limitation
- 📌 Very low ROCE (6.51%) and ROE (6.58%).
- 📌 Extremely high PEG ratio (84.4) indicates poor growth valuation.
- 📌 Negative EPS (-7.12 ₹) raises profitability concerns.
- 📌 Dividend yield (0.11%) is negligible.
📉 Company Negative News
- 📌 Decline in quarterly PAT (295 Cr vs 426 Cr).
- 📌 Reduced DII holdings (-0.81%).
📈 Company Positive News
- 📌 FII holdings increased (+1.15%), showing foreign investor confidence.
🏭 Industry
- 📌 Industry P/E at 32.5, lower than Glenmark’s 38.8, suggesting overvaluation.
- 📌 Pharma sector benefits from global demand, but Glenmark lags peers in efficiency.
🔎 Conclusion
Glenmark is not an ideal candidate for long-term investment due to weak efficiency, negative EPS, and extreme PEG ratio. The ideal entry zone is 1,600–1,750 ₹ for risk-tolerant investors. Current holders should consider reducing exposure near 2,350–2,450 ₹, as long-term holding carries significant valuation and profitability risks.